Investor words

Got venture capital?
Need more investment opportunities to exploit?
Want more investment profits to make and venture?

Welcome to the InvestorDom.com
Venture Marketing Consultant Firm.

  :: Investor words   » ADD EDIT LEAD

Investor words - Investor words investing matters.

Executive Vocabulary Power Words™ (available on either CD or audiocassette) is NOT like other vocabulary learning programs that rely on word memorization.

The term "executive" is an adjective that means: "Having the power, authority, ability or competence to execute."

That's why, unlike other programs that simply teach you new words, Executive Vocabulary helps you to absorb, and teaches you the skill to easily apply, more powerful words. It's a complete vocabulary training system that shows you how to expand your vocabulary, and quickly, easily and fully integrate stronger, more influential words into your day-to-day communications... As if it's second nature.
(www.executive-vocabulary.com)


This Investor words dom is allocated for Investor words associated matters and should be used for Investor words interrelated and correlated Investor words issues only.

We are in the process of creating this Investor words dom category and welcome recommended investor readings and ideas from our audience. We will, of course, be adding a few choice items from our own investor articles and investor tips, but will definitely consider other investor contributions based on their investing potential value to our investors base! Thank you in advance.

Investor words - Investor venture cognitive impact.
It's always the smart ones who seem to know first:
Where, When and How to set/get Investor words.

to be continued ...
You never know what the future hold. Online-investing Venture-investing Investor-opportunity


SmallCap BIOTECH Report
INVESTING IN EMERGING BIOTECH STOCKS

:: COMPANY SPOTLIGHT ::.
Bio-Matrix Scientific Group Inc.
Driving $75 billion dollar a year Biotechnology and Medical Device industries is the demand for new products that improve patient safety, decrease healthcare cost, and most importantly enhance human life.
Symbol: BMXG Trading Price: $0.12


About Bio-Matrix Scientific Group Inc.:
Bio-Matrix Scientific Group Inc. is a San Diego based development stage company in the business of medical devices and monitoring systems research, development and commercialization. Bio-Matrix Scientific Group Inc. is aligning itself with partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems. Its polymer coating on medical devices will ensure that cell transference is done with minimal damage to cells. This should lead to better yields in stem cell extraction, along with better outcomes for patients in tissue management procedures.

Recent News: A spokesperson for the Company said that its Board of Directors plans to spin-off 6,035,501 shares of the common stock of Frezer, Inc., a wholly owned
subsidiary of Bio-Matrix Scientific Group, to BMXG shareholders of record as of May 31, 2005.
This represents one share of Frezer, Inc. for every one share of Bio-Matrix Scientific Group Inc. (Pink Sheets:BMXG) owned post reverse split.

"Ground floor" Company Enters Production Phase

Bio-Matrix Scientific Group Inc., announced that Collective Technologies will manufacture Bio-Matrix's first set of Stem Cell Devices. The Company anticipates having this set of instruments sometime within the next two weeks. BMXG also recently finalized applications for 3 new devices.

This is the first step towards full production of these devices. This first set of devices will be used for its 510(k) testing, trade shows and presentations to Physicians and Researchers. "Collective Technologies enables us to manufacture products in the most efficient and cost-effective way possible," noted Brian Pockett, Managing Director and COO of Bio-Matrix Scientific. "We have been impressed by Collective Technologies' quality record, responsiveness and flexibility - all of which are critical to our production objectives." Bio-Matrix sees this event as nearing a point at which the Company "green-lights" full production of its stem cell and tissue management instruments.


"REAL DEAL" MANAGEMENT
Philip Watts, Ph.D., the Company's Director of Research and Development, highly recognized in his field.
James L. Lambert, Ph.D., as its Bio-Instrument Scientific Advisor. Dr. Lambert specializes in the development of next generation bio-instrumentation for use in medical research. Dr. Lambert has been with the Jet Propulsion Laboratory for 17 years, and for the last five years he has served as the Technical Group Supervisor of the Intelligent Instrument and Systems Technology Group. Dr. Lambert leads a multidisciplinary group whose members have advanced degrees in chemistry, biology, electrical engineering, and computer science. The charter of the group is to develop advanced in situ instruments and sensors for NASA and other agencies.
Geoffrey O'Neill, Ph.D. President of the Company. Dr. O'Neill most recently served as Director of Stem Cell Laboratories and Scientific Research for Cryo-Cell International Inc. (OTC: CCEL). Cryo-Cell International represents themselves as the world's largest U-Cord stem cell banking firm. "The appointment of Dr. O'Neill as President of Bio-Matrix Scientific Group Inc. signals our Company's aggressive growth plans in stem cell research devices, biomedical devices and the continued growth in the development of our Stem Cell Cryogenic Banks," said Brian Pockett, Managing Director and COO of Bio-Matrix Scientific

PRODUCT DEVELOPMENT
Stem Cell Cryogenics
Instrumentation for Stem Cell Research and Tissue
Management
Non-Invasive Bio-Systems Monitoring and Measuring Devices
Niche Medical Device Instrumentation
The Company has recently filed a provisional patent application with the U. S. Patent Office. It anticipates numerous utility patents will result from this filing.

Investment Prosective:
Bio-Matrix has a four pronged revenue strategy each with a different trajectory and different inflection points.
The company is spreading its risk over different operating segments with varying investment requirement and levels of risk.
Larger companies in the medical device industry are aggressive and smaller companies are always takeover targets.

Potential of BMXG:
The market size of the segments it has chosen to operate in is huge. The tissue management instruments market size alone is $860 million.
A provisional patent application has already been filed and more are in the pipeline.

Investor words Advertisements:

Got venture capital?
Need more investment opportunities to exploit?
Want more investment profits to make and venture?

Welcome to the InvestorDom.com
Venture Marketing Consultant Firm.